{"pmid":32461193,"title":"Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.","text":["Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.","Clin Immunol","Vojdani, Aristo","Kharrazianb, Datis","32461193"],"journal":"Clin Immunol","authors":["Vojdani, Aristo","Kharrazianb, Datis"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461193","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.clim.2020.108480","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521504428032,"score":9.490897,"similar":[{"pmid":32303592,"title":"Human leukocyte antigen susceptibility map for SARS-CoV-2.","text":["Human leukocyte antigen susceptibility map for SARS-CoV-2.","Genetic variability across the three major histocompatibility complex (MHC) class I genes (human leukocyte antigen [lsqb]HLA[rsqb] A, B, and C) may affect susceptibility to and severity of severe acute respiratory syndrome 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). We execute a comprehensive in silico analysis of viral peptide-MHC class I binding affinity across 145 HLA -A, -B, and -C genotypes for all SARS-CoV-2 peptides. We further explore the potential for cross-protective immunity conferred by prior exposure to four common human coronaviruses. The SARS-CoV-2 proteome is successfully sampled and presented by a diversity of HLA alleles. However, we found that HLA-B*46:01 had the fewest predicted binding peptides for SARS-CoV-2, suggesting individuals with this allele may be particularly vulnerable to COVID-19, as they were previously shown to be for SARS (Lin M, Tseng H-K, Trejaut JA, Lee H-L, Loo J-H, Chu C-C, Chen P-J, Su Y-W, Lim KH, Tsai Z-U, Lin R-Y, Lin R-S, Huang C-H. BMC Med Genet 4:9. 2003.). Conversely, we found that HLA-B*15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides that are shared among common human coronaviruses, suggesting it could enable cross-protective T-cell based immunity. Finally, we report global distributions of HLA types with potential epidemiological ramifications in the setting of the current pandemic.IMPORTANCE Individual genetic variation may help to explain different immune responses to a virus across a population. In particular, understanding how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease. HLA typing can be fast and inexpensive. Pairing HLA typing with COVID-19 testing where feasible could improve assessment of viral severity in the population. Following the development of a vaccine against SARS-CoV-2, the virus that causes COVID-19, individuals with high-risk HLA types could be prioritized for vaccination.","J Virol","Nguyen, Austin","David, Julianne K","Maden, Sean K","Wood, Mary A","Weeder, Benjamin R","Nellore, Abhinav","Thompson, Reid F","32303592"],"abstract":["Genetic variability across the three major histocompatibility complex (MHC) class I genes (human leukocyte antigen [lsqb]HLA[rsqb] A, B, and C) may affect susceptibility to and severity of severe acute respiratory syndrome 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). We execute a comprehensive in silico analysis of viral peptide-MHC class I binding affinity across 145 HLA -A, -B, and -C genotypes for all SARS-CoV-2 peptides. We further explore the potential for cross-protective immunity conferred by prior exposure to four common human coronaviruses. The SARS-CoV-2 proteome is successfully sampled and presented by a diversity of HLA alleles. However, we found that HLA-B*46:01 had the fewest predicted binding peptides for SARS-CoV-2, suggesting individuals with this allele may be particularly vulnerable to COVID-19, as they were previously shown to be for SARS (Lin M, Tseng H-K, Trejaut JA, Lee H-L, Loo J-H, Chu C-C, Chen P-J, Su Y-W, Lim KH, Tsai Z-U, Lin R-Y, Lin R-S, Huang C-H. BMC Med Genet 4:9. 2003.). Conversely, we found that HLA-B*15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides that are shared among common human coronaviruses, suggesting it could enable cross-protective T-cell based immunity. Finally, we report global distributions of HLA types with potential epidemiological ramifications in the setting of the current pandemic.IMPORTANCE Individual genetic variation may help to explain different immune responses to a virus across a population. In particular, understanding how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease. HLA typing can be fast and inexpensive. Pairing HLA typing with COVID-19 testing where feasible could improve assessment of viral severity in the population. Following the development of a vaccine against SARS-CoV-2, the virus that causes COVID-19, individuals with high-risk HLA types could be prioritized for vaccination."],"journal":"J Virol","authors":["Nguyen, Austin","David, Julianne K","Maden, Sean K","Wood, Mary A","Weeder, Benjamin R","Nellore, Abhinav","Thompson, Reid F"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303592","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1128/JVI.00510-20","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491061272578,"score":55.034245},{"pmid":32408068,"title":"What about the original antigenic sin of the humans versus SARS-CoV-2?","text":["What about the original antigenic sin of the humans versus SARS-CoV-2?","Med Hypotheses","Roncati, Luca","Palmieri, Beniamino","32408068"],"journal":"Med Hypotheses","authors":["Roncati, Luca","Palmieri, Beniamino"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408068","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.mehy.2020.109824","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845371858944,"score":55.034245},{"pmid":32426212,"pmcid":"PMC7231734","title":"Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.","text":["Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.","The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, as pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV, and from infected or immunized mice. Our results show that, while cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV, but also has implications for immunogen design and vaccine development.","Cell Rep","Lv, Huibin","Wu, Nicholas C","Tak-Yin Tsang, Owen","Yuan, Meng","Perera, Ranawaka A P M","Leung, Wai Shing","So, Ray T Y","Chun Chan, Jacky Man","Yip, Garrick K","Hong Chik, Thomas Shiu","Wang, Yiquan","Chung Choi, Chris Yau","Lin, Yihan","Ng, Wilson W","Zhao, Jincun","Poon, Leo L M","Peiris, J S Malik","Wilson, Ian A","Mok, Chris K P","32426212"],"abstract":["The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, as pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV, and from infected or immunized mice. Our results show that, while cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV, but also has implications for immunogen design and vaccine development."],"journal":"Cell Rep","authors":["Lv, Huibin","Wu, Nicholas C","Tak-Yin Tsang, Owen","Yuan, Meng","Perera, Ranawaka A P M","Leung, Wai Shing","So, Ray T Y","Chun Chan, Jacky Man","Yip, Garrick K","Hong Chik, Thomas Shiu","Wang, Yiquan","Chung Choi, Chris Yau","Lin, Yihan","Ng, Wilson W","Zhao, Jincun","Poon, Leo L M","Peiris, J S Malik","Wilson, Ian A","Mok, Chris K P"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426212","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.celrep.2020.107725","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728782766083,"score":54.60531},{"pmid":32504061,"title":"SARS-CoV-2 cross-reactivity in healthy donors.","text":["SARS-CoV-2 cross-reactivity in healthy donors.","Nat Rev Immunol","van der Heide, Verena","32504061"],"journal":"Nat Rev Immunol","authors":["van der Heide, Verena"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504061","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1038/s41577-020-0362-x","topics":["Mechanism"],"weight":1,"_version_":1668892488331427841,"score":54.23593},{"pmid":32422894,"title":"A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity?","text":["A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity?","The S glycoprotein of coronaviruses is important for viral entry and pathogenesis with most variable sequences. Therefore, we analyzed the S gene sequences of SARS-CoV-2 to better understand the antigenicity and immunogenicity of this virus in this study. In phylogenetic analysis, two subtypes (SARS-CoV-2a and -b) were confirmed within SARS-CoV-2 strains. These two subtypes were divided by a novel synonymous mutation of D614G. This may play a crucial role in the evolution of SARS-CoV-2 to evade the host immune system. The region containing this mutation point was confirmed as a B-cell epitope located in the S1 domain, and SARS-CoV-2b strains exhibited severe reduced antigenic indexes compared to SARS-CoV-2a in this area. This may allow these two subtypes to have different antigenicity. If the two subtypes have different serological characteristics, a vaccine for both subtypes will be more effective to prevent COVID-19. Thus, further study is urgently required to confirm the antigenicity of these two subtypes.","Vaccines (Basel)","Kim, Sung-Jae","Nguyen, Van-Giap","Park, Yong-Ho","Park, Bong-Kyun","Chung, Hee-Chun","32422894"],"abstract":["The S glycoprotein of coronaviruses is important for viral entry and pathogenesis with most variable sequences. Therefore, we analyzed the S gene sequences of SARS-CoV-2 to better understand the antigenicity and immunogenicity of this virus in this study. In phylogenetic analysis, two subtypes (SARS-CoV-2a and -b) were confirmed within SARS-CoV-2 strains. These two subtypes were divided by a novel synonymous mutation of D614G. This may play a crucial role in the evolution of SARS-CoV-2 to evade the host immune system. The region containing this mutation point was confirmed as a B-cell epitope located in the S1 domain, and SARS-CoV-2b strains exhibited severe reduced antigenic indexes compared to SARS-CoV-2a in this area. This may allow these two subtypes to have different antigenicity. If the two subtypes have different serological characteristics, a vaccine for both subtypes will be more effective to prevent COVID-19. Thus, further study is urgently required to confirm the antigenicity of these two subtypes."],"journal":"Vaccines (Basel)","authors":["Kim, Sung-Jae","Nguyen, Van-Giap","Park, Yong-Ho","Park, Bong-Kyun","Chung, Hee-Chun"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32422894","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/vaccines8020220","keywords":["covid-19","sars-cov-2","antigenicity","spike protein"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728879235073,"score":52.87839}]}